Reading Your GI-MAP Results: A Practical Guide

Status: ✅ Published | Edited by Virgil | 2026-03-01 Primary Keyword: GI-MAP interpretation guide Word Count: ~1,800 words Format: Q&A / Support Article

---

Part of the GI-MAP Interpretation Guide → | Lab Interpretation Hub →

---

Introduction

You just ran a GI-MAP on a patient and the 6-page report is staring back at you. You can see the numbers. You can see the H's and HH's. But interpreting it — knowing what to act on, what to monitor, and what the gut is actually telling you about the rest of the body — is a different skill entirely.

This guide walks through the GI-MAP as a working practitioner would: section by section, in clinical priority order, with the context you need to connect findings to symptoms. We'll spend the most time on beta-glucuronidase — the metabolic marker hiding in page 5 that's often driving the whole hormonal picture your patient came in with.

---

How do I read GI-MAP results step by step?

Don't read the GI-MAP top to bottom. Start with the red flags.

The report flows in a logical sequence — pathogens → commensals → opportunistic bacteria → fungi/parasites → digestion → immune/inflammation → metabolic. But that's not the order you should read it in clinically. Page order ≠ clinical priority order.

Here's the framework that works:

Step 1 — Pathogens first. Any positive result in the pathogen section (H. pylori, Campylobacter, C. difficile, E. coli O157, etc.) is actionable regardless of everything else on the report. Active infections set the priority hierarchy. Don't chase dysbiosis while an infection is running.

Step 2 — Jump to immune/inflammation markers. Calprotectin tells you how much mucosal inflammation is present. SIgA tells you how robust the immune defense is. These two markers frame the urgency of the entire clinical picture. High calprotectin plus elevated pathogens = active inflammatory process requiring intervention now. Low SIgA plus dysbiosis = compromised mucosal immunity, which changes your timeline and approach.

Step 3 — Read opportunistic bacteria and fungi together. This is the dysbiosis picture. Elevated Klebsiella, Proteus, or Candida in the context of low Lactobacillus and absent Faecalibacterium prausnitzii tells a coherent story of ecological disruption. Look for patterns, not individual findings.

Step 4 — Digestion markers. Elastase-1 is your pancreatic exocrine function read. Below 200 µg/g suggests exocrine pancreatic insufficiency (EPI); below 100 is severe and will compromise everything downstream. You can't restore a microbiome in a patient who isn't digesting their food.

Step 5 — Metabolic section, specifically beta-glucuronidase. This marker lives at the end of the report and gets skipped more than any other. That's a mistake. Beta-glucuronidase is often the most important number on the page for your estrogen-dominant patients — more on this below.

[CHART: GI-MAP Section Map — Tiered priority pyramid showing all 7 sections of the GI-MAP report with clinical priority ranking. Top tier: Pathogens + Immune/Inflammation (act immediately). Middle tier: Opportunistic Bacteria + Fungi. Lower tier: Commensals + Digestion. Base: Metabolic markers including β-glucuronidase.] AI prompt: "Clean medical infographic showing 7 sections of a gut microbiome test report arranged as a tiered pyramid. Top tier: Pathogens + Immune markers (act immediately). Middle tier: Commensals + Fungi. Bottom tier: Digestion + Metabolic. Modern clinical style, muted blues and greens."

---

What does beta-glucuronidase mean on the GI-MAP?

Beta-glucuronidase is the hidden estrogen marker on every GI-MAP. Elevated levels mean your patient's gut is recycling estrogen instead of excreting it.

This is the section to spend time on.

The enzyme and what it does

Beta-glucuronidase (β-glucuronidase) is an enzyme produced by gut bacteria — primarily gram-negative organisms like E. coli, Bacteroides species, and some Clostridium — that cleaves glucuronic acid from glucuronide-conjugated compounds in the intestinal lumen. The liver's job is to conjugate estrogens (and many other compounds) to glucuronic acid before excreting them in bile — this conjugation essentially inactivates them for elimination. When β-glucuronidase activity is elevated, gut bacteria are deconjugating those estrogens faster than they can be excreted, reactivating them and allowing them to be reabsorbed through the intestinal wall back into portal circulation.¹

This is the estrobolome in action. The estrobolome refers to the aggregate of gut microbial genes capable of metabolizing estrogens — and β-glucuronidase is its primary mechanism of action.²

[DIAGRAM: Beta-glucuronidase / Estrobolome cycle — Four-step circular diagram showing: 1) Liver conjugates estrogen (inactivates) → 2) Excreted in bile into intestine → 3) Gut bacteria produce β-glucuronidase, deconjugating estrogen (reactivates) → 4) Reabsorbed into bloodstream. Warm clinical palette, simple anatomical illustration style.]

Why it matters clinically

When β-glucuronidase is elevated:

• Estrogen dominance patterns emerge or worsen — even when ovarian production is normal
• DUTCH results may show high estrogen metabolites (or may look "normal" while symptoms persist, because the reabsorbed estrogen is harder to capture in urine)
• PMS, heavy periods, fibrocystic breast tissue, and endometriosis risk increase — all estrogen-responsive tissues respond to the recirculating load
• Breast cancer risk elevation — a 2023 review in Frontiers in Endocrinology found gut microbial β-glucuronidase is a significant regulator of circulating estrogen and a meaningful contributor to estrogen-related cancer risk³

It's not only estrogen. β-glucuronidase also deconjugates bilirubin (contributing to elevated indirect bilirubin in some patients), certain toxins processed through the liver's glucuronidation pathway, and glucuronide-conjugated drugs — including NSAIDs, opioids, and some antibiotics. Patients on these medications with high β-glucuronidase may experience inconsistent drug effects or increased GI side effects as the enterohepatic circulation is disrupted.

What drives β-glucuronidase up

• Dysbiosis — particularly gram-negative overgrowth (Klebsiella, Bacteroides, Proteus)
• Low fiber intake — beneficial bacteria that downregulate β-glucuronidase (Akkermansia, Bifidobacterium, Lactobacillus) require fermentable fiber to thrive
• High saturated fat diet — promotes gram-negative bacterial species
• Antibiotic history — depletes the commensal bacteria that keep β-glucuronidase-producing species in check

What brings it down

• Dietary fiber and prebiotics — feed the commensal species that outcompete β-glucuronidase producers
• Targeted probiotics — Lactobacillus and Bifidobacterium strains directly reduce β-glucuronidase activity
• Calcium-D-glucarate — a natural compound that inhibits β-glucuronidase directly, widely used in FM for estrogen support
• Treating the underlying dysbiosis — if Klebsiella or Bacteroides overgrowth is driving the enzyme, addressing the dysbiosis is the root fix

Reference range: Diagnostic Solutions Laboratory typically flags β-glucuronidase above 1,600 U/g as elevated (H), though the specific cutoff may vary slightly by lab version. Values above this threshold should prompt clinical attention, particularly in female patients with hormonal symptoms.

Sources: ¹ Baker JM et al. Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas. 2017. PMID 28778332 | ² Ervin SM et al. Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome. ACS Chem Biol. 2019. PMC6901331 | ³ Wang Y et al. Gut microbial beta-glucuronidase: a vital regulator in female estrogen metabolism. Front Endocrinol. 2023. PMC10416750

---

What are the normal ranges on the GI-MAP?

GI-MAP uses quantitative PCR, not culture — the numbers are DNA copies per gram of stool, and the ranges reflect what's seen in a general population, not a functional medicine optimal.

The GI-MAP reports bacterial findings as DNA copies per gram of stool, measured via qPCR. This is a fundamentally different methodology than a culture-based stool test: it detects organisms that won't grow in standard culture conditions, and it's quantitative — the number carries clinical weight, not just the presence/absence.

Results are flagged as:

• H — above the reference range upper limit; clinically significant
• HH — substantially above reference range; high clinical urgency
• Not Detected — below the detection threshold (not the same as absent)

[TABLE: GI-MAP Reference Range Quick Guide] Suggested 3-column format: Marker | Reference Range | Clinical Meaning of Elevation

Marker	Reference Range	Clinical Meaning of Elevation
β-glucuronidase	< 1,600 U/g	Estrobolome disruption; increased estrogen recirculation
Calprotectin	< 50 µg/g	Mucosal inflammation; > 200 µg/g warrants GI specialist referral
SIgA	510–2,040 µg/mL	Low = compromised mucosal immune defense
Elastase-1	> 200 µg/g	< 200 = exocrine pancreatic insufficiency; < 100 = severe EPI
Zonulin	< 107 ng/mL	Elevated = increased intestinal permeability ("leaky gut")
Akkermansia muciniphila	Detected	Absent or very low = mucosal integrity at risk
Faecalibacterium prausnitzii	Detected	Absent = reduced SCFA production, mucosal inflammation risk
Lactobacillus (total)	Detected	Low = reduced colonization resistance, immune dysregulation

Source: Diagnostic Solutions Laboratory GI-MAP reference guide

A critical nuance for FM practitioners: the reference ranges are derived from a general healthy adult population, which is not the same as functional medicine optimal. Low-normal Akkermansia muciniphila and Faecalibacterium prausnitzii matter — both are keystone species for mucosal integrity and SCFA production, and trending low even within normal range is a meaningful clinical signal. Don't dismiss "technically in range" findings in symptomatic patients.

Key benchmarks to know:

• Elastase-1 < 200 µg/g → exocrine pancreatic insufficiency; < 100 µg/g → severe EPI
• Calprotectin > 50 µg/g → mucosal inflammation; > 200 → IBD territory, GI specialist referral warranted
• SIgA low-normal in the context of dysbiosis → compromised mucosal immune defense; aggressive antimicrobials before rebuilding SIgA often backfires
• β-glucuronidase > 1,600 U/g → estrobolome disruption; see section above

---

What GI-MAP sections should I prioritize when reading results?

The triage framework: infections before dysbiosis, inflammation severity before treatment intensity, and β-glucuronidase before you write a hormone protocol.

Experienced GI-MAP readers follow a consistent triage logic:

Infections first, dysbiosis second. The presence of an active pathogen changes the entire treatment approach. If H. pylori is detected, that's the priority — not the Candida, not the low Akkermansia. Treat the infection, retest, then address what remains. Attempting to modulate dysbiosis in an actively infected gut wastes the protocol and the patient's money.

Inflammation severity frames urgency. Calprotectin is your thermometer. A β-glucuronidase of 2,500 with calprotectin of 30 and no pathogens is a different clinical situation than the same β-glucuronidase with calprotectin of 180 and elevated Klebsiella. The former is a slower metabolic and hormonal issue; the latter requires active intestinal anti-inflammatory work first.

Low SIgA changes the plan. A patient with significantly suppressed secretory IgA and dysbiosis needs mucosal immune rebuilding (colostrum, zinc, L-glutamine, SIgA-supportive probiotics) before aggressive antimicrobials. Hitting dysbiosis hard in an immunocompromised mucosa tends to produce worse symptoms and poor tolerance.

Metabolic markers tell you what the bacteria are doing, not just who's there. Microbial composition (who's present) is informative. Functional output (what they're producing) is actionable. β-glucuronidase is the clearest functional marker on the panel — it tells you what your patient's microbiome is actively doing to their estrogen metabolism, right now.

Connect to the patient, not just the report. Elevated Klebsiella in an asymptomatic patient is different from the same finding in an exhausted, brain-fogged, estrogen-dominant patient. The report is a tool. The clinical context is the practice.

---

Case Example: The Estrogen Dominance With a Gut Address

Patient: 38-year-old female presenting with progressive bloating, fatigue, and worsening PMS over 18 months. DUTCH panel shows elevated estrogen metabolites consistent with estrogen dominance pattern.

GI-MAP findings:

• Pathogens: Negative across all
• Commensals: Low Lactobacillus total, Faecalibacterium prausnitzii absent
• Opportunists: Klebsiella pneumoniae elevated (HH)
• β-glucuronidase: HH — 2,450 U/g (ref < 1,600)
• Calprotectin: 80 µg/g (mildly elevated)
• SIgA: Low-normal

Clinical read:

The estrogen dominance wasn't primarily ovarian — it was intestinal. Elevated β-glucuronidase driven by Klebsiella-dominant dysbiosis was systematically deconjugating estrogens in the gut and recycling them back into circulation. The mild calprotectin elevation confirmed low-grade mucosal inflammation. The low SIgA explained the persistence of the dysbiosis: her gut immune defense was too compromised to keep the Klebsiella population in check.

Protocol (90 days):

• Berberine 500 mg TID (addresses Klebsiella directly)
• Lactobacillus/Bifidobacterium combination probiotic
• Calcium-D-glucarate 500 mg BID
• High-fiber prebiotic support
• SIgA support: colostrum + zinc carnosine

Outcome: β-glucuronidase normalized to 1,100 U/g at 90-day retest. Klebsiella reduced to trace. Faecalibacterium prausnitzii now detected. PMS symptoms resolved. No hormonal intervention used.

Teaching point: This is why the GI-MAP belongs in every estrogen-dominant workup. The hormone issue had a gut address, and it showed up on page 5 of the report in a single number.

---

Internal Links

→ GI-MAP Interpretation Guide: All Findings — Complete reference for every marker on the panel → Lab Interpretation Hub — All functional lab guides in one place → GI-MAP Dysbiosis Treatment Protocols — Once you've read the results, see the treatment framework → GI-MAP vs. Comprehensive Stool Test — Not sure which to order? Here's the comparison

---

Summary

The GI-MAP interpretation guide in four principles:

1. Read in priority order — pathogens → inflammation → dysbiosis → digestion → metabolic
2. The number matters — qPCR is quantitative; how elevated tells you how urgent
3. Beta-glucuronidase is the estrogen marker hiding in the metabolic section — don't skip it in any hormonal case
4. Population-normal isn't functional-optimal — apply clinical context to every finding

---

Documenting GI-MAP results takes time. See how HANS automates FM documentation → View Plans & Pricing

Every GI-MAP generates pages of findings that need to live in a note, a treatment plan, and a patient summary. HANS reads the report and builds the documentation — so you can spend the 30 minutes you just saved on the next patient.

→ Start Your Free Trial

---

References:

1. Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas. 2017;103:45-53. PMID: 28778332
2. Ervin SM, Li H, Lim L, et al. Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens. ACS Chem Biol. 2019;14(12):2586-2598. PMC6901331
3. Wang Y, Guo J, He Z, et al. Gut microbial beta-glucuronidase: a vital regulator in female estrogen metabolism. Front Endocrinol (Lausanne). 2023;14:1152612. PMC10416750
4. Diagnostic Solutions Laboratory. GI-MAP Reference Guide and Interpretive Notes. 2024.